Linked Life Data

18186700

Source:http://linkedlifedata.com/resource/pubmed/id/18186700

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-1-11
pubmed:abstractText
Societal expectations about drug safety and efficacy are rising while productivity in the pharmaceutical industry is falling. In 2004, the US Food and Drug Administration introduced the Critical Path Initiative with the intent of modernizing drug development by incorporating recent scientific advances, such as genomics and advanced imaging technologies, into the process. An important part of the initiative is the use of public-private partnerships and consortia to accomplish the needed research. This article explicates the reasoning behind the Critical Path Initiative and discusses examples of successful consortia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0066-4219
pubmed:author
pubmed:issnType
Print
pubmed:volume
59
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-12
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
The FDA critical path initiative and its influence on new drug development.
pubmed:affiliation
Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857, USA. Janet.Woodcock@fda.hhs.gov
pubmed:publicationType
Journal Article, Review